Towards a cure for early rheumatoid arthritis

Lead Research Organisation: King's College London
Department Name: Immunology Infection and Inflam Diseases

Abstract

Joint inflammation may either resolve spontaneously or evolve into rheumatoid arthritis (RA). RA is a chronic disease which causes joint pain and swelling, and ultimately deformity and disability. People with RA who are diagnosed and treated early do much better than those in whom diagnosis and treatment are delayed. They have less joint damage and long term disability. The best possible response to a drug, a clinical state called remission in which there are no detectable signs or symptoms of arthritis, is only achieved in a minority of people. New research is urgently needed to identify which subgroups of people with arthritis are most likely to achieve clinical remission without the need for drug therapy, or in response to arthritis drugs. This would mean that only those people who need treatment receive it, thus reducing the costs of treatment and the risk of side effects. The aims of our research project are to enable the delivery of the right treatment to the right patient at the right time. We aim to establish how to measure the state of clinical remission not only at the bedside but also in the laboratory (eg using new ways to visualise affected joints and combining these with blood tests that assess the health of the immune system), and to identify individuals who may be at risk of developing RA in the future. To achieve these objectives, we will work closely with the pharmaceutical industry to collect information about all clinical studies that have been undertaken in patients with RA. We will then study the characteristics of patients with RA who have been recruited to clinical trials and received either (a) placebo (a lookalike drug but with no effects), or (b) active drug, and use this information to see if we can identify the factors that predict spontaneous or treatment-induced clinical remission. We will also set up a new, UK-wide research study of early RA patients to investigate this in more detail. These patients will receive treatment according to nationally approved guidelines. We will observe them in detail, collecting information about their arthritis and how they respond to teatment. Finally, we will undertake some studies to see if it possible to identify healthy individuals who are likely to develop RA in the future. This could pave the way for new ways to treat, or even prevent, early arthritis.

Technical Summary

New cases of inflammatory polyarthritis (IP) may either resolve spontaneously or evolve into rheumatoid arthritis (RA). Early diagnosis and prompt therapy with tight control have been shown, in clinical trials, to alter the long-term course of early RA towards a more benign outcome by limiting structural damage and long term disability. Nonetheless, clinical remission is only achieved in a minority of subjects with early RA, and sustained drug-free remission remains a rare event. There is therefore a major unmet need to identify the characteristics of those individuals most likely to achieve clinical remission either spontaneously or in response to specific drug therapies so that new and existing therapies can be targeted to the right patient populations. Thus, identification of accurate predictors of spontaneous resolution, mild disease in early RA, and treatment response would prevent patients being exposed unnecessarily to potentially toxic therapies and permit stratification of patient populations in clinical trial and clinic settings. There is also a need to accurately define clinical and biological outcomes that unambiguously reflect drug efficacy. The aims of this research are to establish reproducible and clinically relevant criteria for ?biological remission states? that incorporate imaging and immune phenotypes, to establish the key predictors of clinical remission in early IP and RA patients and to identify individuals at high risk of developing RA in whom prognostic factors for remission and ongoing active disease can be validated. To achieve these objectives, we will first assemble an inventory of relevant UK clinical cohorts and clinical trials. We will then collate anonymised patient-level data from RA patients randomised, in controlled clinical trials, to receive (a) placebo or (b) active drug, and use this information to establish the characteristics, frequency, duration and clinical consequences of spontaneous and drug-induced clinical remission. A new, UK-wide longitudinal observational study of early RA patients will be established, in which patients will receive intensive treatment according to NICE guidelines. Clinical, imaging and immunological assessments, including novel in vivo assays of resolution, will be undertaken, and the data used to identify further biological predictors and descriptors of the remission state. Finally, we will undertake a feasibility study using existing EPIC/NOAR and UK Biobank cohorts to characterise individuals captured prior to RA onset based on demographic, genotypic and autoantibody profiles. This will provide novel insights into the very earliest phase of the disease and provide a framework for disease prevention strategies in the future.

Organisations

Publications

10 25 50

publication icon
Bechman K (2020) Placebo Response in Rheumatoid Arthritis Clinical Trials. in The Journal of rheumatology

publication icon
Cope AP (2017) Emerging therapies for pre-RA. in Best practice & research. Clinical rheumatology

 
Description Arthritis Research UK Rare Diseases Workshop 2017
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Arthritis Research UK Strategic Workshop - Stacking the Odds Towards a Cure - Versus Arthritis London 2018
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description EULAR 2019 Planning Committee, Amsterdam, 2018
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
 
Description MRC Newcastle University Review
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Model collaborative partnerships with industry
Geographic Reach National 
Policy Influence Type Citation in other policy documents
 
Description NIHR Bioresource Meeting
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Science and Society perspectives article published in Nature Reviews Rheumatology
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact This article highlighted the lessons learnt from Industry-Academic collaborations, providing an operational model for future consortia.
 
Description BRC Clinical Training Fellowship
Amount £60,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description EU Horizon 2020
Amount £6,000,000 (GBP)
Organisation European Union 
Sector Public
Country European Union (EU)
Start 07/2017 
End 06/2022
 
Description EU IMI2 (Rheuma Tolerance for Cure [RTCure]) - KCL
Amount € 6,000,000 (EUR)
Funding ID 777357 
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Public
Country Belgium
Start 06/2017 
End 05/2022
 
Description EU IMI2 (Rheuma Tolerance for Cure [RTCure]) - Newcastle
Amount € 6,000,000 (EUR)
Funding ID 777357 
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Public
Country Belgium
Start 06/2017 
End 05/2022
 
Description Immune-mediated inflammatory disease biobanks in the UK - IMIDBio_UK
Amount £218,084 (GBP)
Funding ID MR/R014191/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2017 
End 09/2020
 
Description Investigation into serum interferon-a as a prognostic marker of clinical response in early RA
Amount £15,143 (GBP)
Organisation British Society for Rheumatology (BSR) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2018 
End 08/2019
 
Description MATURA
Amount £550,614 (GBP)
Funding ID BH137922 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2014 
End 03/2018
 
Description MRC/ABPI Immunity and Inflammation Initiative
Amount £109,465 (GBP)
Funding ID G1001516/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2013 
End 12/2013
 
Description NIHR Manchester Biomedical Research Centre
Amount £28,500,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description The ALTO study
Amount £931,136 (GBP)
Funding ID IM1010-865 
Organisation Bristol-Myers Squibb 
Sector Private
Country United States
Start 06/2020 
End 01/2023
 
Description The TRESORA study
Amount £166,386 (GBP)
Organisation Janssen Research & Development 
Sector Private
Country Global
Start 07/2017 
End 06/2019
 
Title Chiltern ACTIVATE 
Description With additional funding the TACERA study team were able to engage a CRO - Chiltern - to contribute to study set up, adopting their Chiltern ACTIVATE programme, which focusses on robust and timely R&D approvals for study site set up. 
Type Of Material Improvements to research infrastructure 
Year Produced 2013 
Provided To Others? Yes  
Impact This strategy accelerated R&D approvals and study site set up. 
URL http://www.chiltern.com/services_globalclinical.aspx
 
Title RA-MAP Systems Model 
Description Network-based and cross-platform models of response to treatment in rheumatoid arthritis. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2018 
Provided To Others? No  
Impact Currently in development the model and data to be made available by 2020. 
URL https://research.ncl.ac.uk/ra-map/
 
Title The RA-MAP Immunological Toolkit 
Description This development of this suite of immune biomarkers - the toolkit - is the major objective of the RA-MAP Consortium. It will be developed from biological material derived at 3 monthly intervals from TACERA study participants. 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact In progress. Ongoing collaborations to 1) validate MATURA methotrexate responders and 2) validate Newcastle interferon gene signature. 
URL https://research.ncl.ac.uk/ra-map/
 
Title The immunological toolkit 
Description This development of this suite of immune biomarkers - the toolkit - is the major objective of the RA-MAP Consortium. It will be developed from biological material derived at 3 monthly intervals from TACERA study participants. 
Type Of Material Biological samples 
Provided To Others? No  
Impact This is work in progress. 
 
Title EPIC Norfolk 
Description EPIC Norfolk Collaborate with us on our work examining lifestyle and metabolic factors that predict onset of RA in the general population in order to help us develop risk prediction models for future RA onset 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact We have established a good collaborative link with EPIC Norfolk and plan a number of analyses over the next 12 months 
 
Title FEMERA: Functional Endotyping Model for Early RA 
Description Projection of multi-dimensional data onto two dimensions for consistency scoring and identification of TNF-reactive and Lymphocytic RA endotypes. 
Type Of Material Computer model/algorithm 
Year Produced 2017 
Provided To Others? Yes  
Impact Application of a method developed by SimOmics permitting identification of endotypes in RA and mapping them to a systems model of RA. 
 
Title IMID-BIO UK Database 
Description Cross-consortia collaboration bringing together databases across the immune-mediated inflammatory diseases. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? No  
Impact Validation of MATURA methotrexate responder signature. Validation of Newcastle interferon gene signature. 
URL https://www.gla.ac.uk/research/az/imid/studies/
 
Title MedSciNet EDC for TACERA study 
Description A study specific Electronic Data Capture (EDC) system has been designed for the TACRA study. This will be the electronic Case Record Form (eCRF) for the study as well as forming part of the Study Management system. The system will also automatically enrol patients once they have been deemed eligible. The EDC system is designed to follow the order of the study assessments and include all the clinical data (incl. Medication history, lifestyle factors questionnaire, DAS28 etc). 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact The clinical dataset will be archived after the TACERA study closure and data will be available to other researchers upon request. 
 
Title PRE-RA: Predictors of Remission in Early RA. 
Description A cross-platform multi-omics model of predictors of remission for stratification of early RA patients. 
Type Of Material Computer model/algorithm 
Year Produced 2017 
Provided To Others? Yes  
Impact In preparation. 
 
Title RA-MAP Predictors of Remission 
Description We have amalgamated 19 datasets provided by the parmaceutical industry into a single dataset. This required understanding an harmonisation of variables as well as re-anonymisation of the individual components of the dataset. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact The datasets will be provided to the MRC Biostatistics Unit at Cambridge. they are now working on identification of predictors of remission or a remission trajectory. 
 
Title RA-MAP Predictors of Remission 
Description We have amalgamated 19 datasets provided by the pharmaceutical industry into a single dataset. This required understanding and harmonisation of variables as well as re-anonymisation of the individual components of the dataset. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? No  
Impact The datasets will be provided to the MRC Biostatistics Unit at Cambridge. They are now working on identification of predictors of remission or a remission trajectory. Draft paper to be submitted Q2 2017. Second paper on transcriptomics data to be submitted Q2 2017. Multi-omics and additional papers in preparation for publication 2017-2018. 
 
Title TranSMART 
Description The Innovative Medicines Initiative eTRIKS team have provided technical support to the RA-MAP informatics team (Mike Barnes lead) to assist in the deployment of an open source datamart (TranSMART) for the RA-MAP projects. The TranSMART provides a useful repository tool for important data (patient clinical data, transcriptomics, metabolomics etc) that are acquired from the RA-MAP projects. The RA-MAP TranSMART is now operational and enabling secure data sharing between consortium members. 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact The Barnes team have propagated the support provided for RA-MAP to enable the deployment of additional TranSMART datamarts for the MRC-PSORT and MRC-MATURA projects. This has created a unique, common datamarts infrastructure across three closely related MRC projects investigating immune-inflammatory disease, creating opportunities for future data integration ad integrated analysis for stratified medicine and drug discovery. 
 
Title TranSMART RA-MAP Multiomics database. 
Description The Innovative Medicines Initiative eTRIKS team have provided technical support to the RA-MAP informatics team (Mike Barnes lead) to assist in the deployment of an open source datamart (TranSMART) for the RA-MAP projects. The TranSMART provides a useful repository tool for important data (patient clinical data, transcriptomics, metabolomics etc) that are acquired from the RA-MAP projects. The RA-MAP TranSMART is now operational and enabling secure data sharing between consortium members. 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact The Barnes team have propagated the support provided for RA-MAP to enable the deployment of additional TranSMART datamarts for the MRC-PSORT and MRC-MATURA projects. This has created a unique, common datamarts infrastructure across three closely related MRC projects investigating immune-inflammatory disease, creating opportunities for future data integration ad integrated analysis for stratified medicine and drug discovery. [Updates from March 2016] We are sharing curated public data in the database with the MRC-MATURA, MRC-PSORT and IMI-etriks projects Knowledge sharing and troubleshooting between these projects has enabled more rapid data curation and data infrastructure development for the project. We have also provided advice and troubleshooting on TranSMART configuration to the MRC-CHART (Juvenile Idiopathic Arthritis) and MRC-Masterplan (SLE) consortia [Updates from March 2017] As a complex, highly curated dataset, the RA-Map TranSMART is serving as an exemplar for development of TranSMART for the the MRC-MATURA, MRC-PSORT and MRC-MASTERPLANS projects. The project is also being used as a successful exemplar for multiple MRC stratified medicine applications. 
 
Description A: RA Centre of Excellence - Birmingham Scientific Meeting. 
Organisation University of Birmingham
Department Birmingham Clinical Trials Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Workshop on fibroblasts by Lilian Nwosu. Presentations my myself on TRAFIC and BioFlare studies.
Collaborator Contribution Equal partners with Glasgow and Birmingham.
Impact See additional awards and publications stemming from the RACE centre.
Start Year 2015
 
Description A: RA Centre of Excellence - Birmingham Scientific Meeting. 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Workshop on fibroblasts by Lilian Nwosu. Presentations my myself on TRAFIC and BioFlare studies.
Collaborator Contribution Equal partners with Glasgow and Birmingham.
Impact See additional awards and publications stemming from the RACE centre.
Start Year 2015
 
Description Association of Physicians Annual Meeting Manchester 2018 
Organisation Manchester University
Country United States 
Sector Academic/University 
PI Contribution Keynote speakers including Doug Turnbull and Andy Burnham. Participation in discussions around the Manchester Health Network.
Collaborator Contribution TBD
Impact TBD
Start Year 2018
 
Description CRO Chiltern Programme 
Organisation Chiltern International
Country United Kingdom 
Sector Private 
PI Contribution n/a
Collaborator Contribution In 2013 Chiltern Activate was employed to facilitate TACERA study (early RA longitudinal study, a part of RA-MAP consortium) set up, which resulted in significant improvement of recruitment process. From 1st April 2014 the Clinical Monitoring team at Chiltern has been re-engaged to support recruitment at poorly performing sites.
Impact The RA-MAP consortium benefitted from this professional partnership by Chiltern's experience in facilitation of clinical study set up and recruitment processes.
Start Year 2013
 
Description CRO Chiltern Programme 
Organisation Chiltern International
Country United Kingdom 
Sector Private 
PI Contribution n/a
Collaborator Contribution In 2013 Chiltern Activate was employed to facilitate TACERA study (early RA longitudinal study, a part of RA-MAP consortium) set up, which resulted in significant improvement of recruitment process. From 1st April 2014 the Clinical Monitoring team at Chiltern has been re-engaged to support recruitment at poorly performing sites.
Impact The RA-MAP consortium benefitted from this professional partnership by Chiltern's experience in facilitation of clinical study set up and recruitment processes.
Start Year 2013
 
Description Euro-Diagnostica 
Organisation Euro Diagnostica
Country Sweden 
Sector Private 
PI Contribution I made an approach to Euro Diagnostica to propose we assess CCP2 antibody status in a population sample to better understand the risk of RA in a community sample of the general population
Collaborator Contribution Euro Diagnostica have supported our work in the EPIC-2-NOAR study by providing CCP2 antibody ELISA kits at a reduced cost for our research studies.
Impact Collaborative partnership involving industry, Cambridge and Manchester as well as UEA
Start Year 2012
 
Description IMI consortium RT-CURE 
Organisation Apitope
Country Belgium 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Johnson & Johnson
Country United States 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Leibniz Association
Department German Rheumatism Research Centre
Country Germany 
Sector Charity/Non Profit 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Leiden University Medical Center
Department Department of Rheumatology
Country Netherlands 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Pfizer Inc
Country United States 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Royal Berkshire Hospital
Department Rheumatology Department
Country United Kingdom 
Sector Hospitals 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation Sanofi
Country Global 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation University Hospital Erlangen
Department Department of Rheumatology and Immunology
Country Germany 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation University of Bath
Department Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation University of Birmingham
Department Institute of Cancer and Genomic Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation University of Glasgow
Department Department of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMI consortium RT-CURE 
Organisation University of Queensland
Country Australia 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle leads WP6 , the clinical trials work package, and contributes to all other WPs. In particular we contribute cohorts to WP2, and immunology/biomarker expertise to WPs 3 and 4. AuToDeCRA 2 is partly supported by RT-CURE. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation King's College London
Department School of Biomedical Sciences KCL
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation Queen Mary University of London
Department School of Biological and Chemical Science QMUL
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation University of Cambridge
Department Cambridge-Africa
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation University of Manchester
Department Mancester Breast Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description Kennedy Institute, Oxford University 
Organisation University of Oxford
Department Kennedy Institute of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution Presentation Towards a Cure for Rheumatoid Arthritis
Collaborator Contribution Feedback and small group discussions with individual PIs and researchers.
Impact Plans for future collaborative research through RACE.
Start Year 2018
 
Description King's Health Partners (Viapath) 
Organisation Viapath
Country United Kingdom 
Sector Private 
PI Contribution n/a
Collaborator Contribution Partnership with King's Health Partners (Viapath) to undertake assays for rheumatoid factor and anti-CCP antibodies, and high sensitivity CRP assays in serum from the first 300 patients recruited to the PREVeNT RA cohort of first degree relatives of patients with RA.
Impact None yet.
Start Year 2014
 
Description King's Health Partners (Viapath) 
Organisation Viapath
Country United Kingdom 
Sector Private 
PI Contribution n/a
Collaborator Contribution Partnership with King's Health Partners (Viapath) to undertake assays for rheumatoid factor and anti-CCP antibodies, and high sensitivity CRP assays in serum from the first 300 patients recruited to the PREVeNT RA cohort of first degree relatives of patients with RA.
Impact None yet.
Start Year 2014
 
Description MATURA Consortium 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation Queen Mary University of London
Department William Harvey Research Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Hertfordshire
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA Consortium 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Collaborator Contribution The genetic basis of treatment responses, and of disease severity.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MRC ABPI RA MAP Project 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I am the UK Chief Investigator on the PREVeNT RA work stream in this MRC ABPI Award
Collaborator Contribution There are 6 core centres involved in this collaboration and in Manchester we lead on several of the Epidemiology Projects
Impact Studies are underway and early papers to follow
Start Year 2011
 
Description MRC ABPI RA MAP Project 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution I am the UK Chief Investigator on the PREVeNT RA work stream in this MRC ABPI Award
Collaborator Contribution There are 6 core centres involved in this collaboration and in Manchester we lead on several of the Epidemiology Projects
Impact Studies are underway and early papers to follow
Start Year 2011
 
Description Partnership between University of Birmingham and Protagen 
Organisation Protagen AG
Country Germany 
Sector Private 
PI Contribution Partnership between UoB and Protagen to look at autoantibody profiles in arthritis associated with anti-PD1 therapy. This arose in part through contacts made at RA-MAP. Transfer of samples governed by MTA.
Collaborator Contribution Partnership between UoB and Protagen to look at autoantibody profiles in arthritis associated with anti-PD1 therapy. This arose in part through contacts made at RA-MAP. Transfer of samples governed by MTA.
Impact None yet (autoantibody profiling in arthritis patients associated with anti-PD1 therapy)
Start Year 2016
 
Description Protagen joins as a new RA-MAP partner 
Organisation Protagen AG
Country Germany 
Sector Private 
PI Contribution Serum samples from early RA cohort (TACERA study, n=275) together with healthy controls (from Vaccine Study, n=50) will be provided to Protagen for autoantibody profiling by Protagen's SeroTag® platform.
Collaborator Contribution Protagen has examined autoantibodies to over 7,000 human proteins in the serum samples provided by the RA-MAP consortium. Protagen AG provided the technological platform, ran the analytical lab work, the statistical analysis and covered its own operational costs.
Impact None yet.
Start Year 2015
 
Description Protagen joins as a new RA-MAP partner 
Organisation Protagen AG
Country Germany 
Sector Private 
PI Contribution Serum samples from early RA cohort (TACERA study, n=275) together with healthy controls (from Vaccine Study, n=50) will be provided to Protagen for autoantibody profiling by Protagen's SeroTag® platform.
Collaborator Contribution Protagen plans on examining autoantibodies to over 7,000 human proteins in the serum samples provided by the RA-MAP consortium. Protagen AG will provide the technological platform, run the analytical lab work, the statistical analysis and cover its own operational costs. Estimated project delivery: July 2016.
Impact None yet.
Start Year 2015
 
Description RA-MAP Consortium Academic Partners 
Organisation RA-MAP Consortium
Country United Kingdom 
Sector Academic/University 
PI Contribution Workpackage 1 of the RA-MAP collaboration is coordinated by King's College London. This involves oversight of: 1) Predictors of remission in RA, the collation of randomised clinical trial patient level data from academic and industry partners to identify Predictors of Remission, led by Manchester University; 2) The TACERA study, a longitudinal observational study of patients with newly diagnosed RA, led by King's College London. 3) the PREVENT RA study, a registry of First Degree Relatives of RA patients, led by Manchester University.
Collaborator Contribution The Workpackage 2 of the RA-MAP collaboration is coordinated by Newcastle University. This involves oversight of: 1) The development of an "immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. 2) Vaccine Substudy on healthy vaccines, led by University of Glasgow. All academic partners contribute to WP1 and WP2 to varying extents. Specific contributions, besides those summarised above include: 1) MRC Biostatistics Unit, University of Cambridge, who have provided Statistical Analysis Plans for each of the research studies. 2) Industry partners provide "in kind" support for a) Study Operations and Coordination b) Bioinformatics, statistics and data analysis expertise c) Data analysis platforms and knowledge management. In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). d) Expertise in Knowledge Management, including provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software
Impact Too early in project to report outputs.
Start Year 2012
 
Description RA-MAP Consortium Industry Partners 
Organisation AbbVie Inc
Country United States 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation Amgen Inc
Country United States 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation F. Hoffmann-La Roche AG
Country Global 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation Janssen Research & Development
Country Global 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description RA-MAP Consortium Industry Partners 
Organisation UCB Pharma
Department UCB Celltech
Country United Kingdom 
Sector Private 
PI Contribution This consortium underpins the programme of work, since the funds were awarded to work in areas of inflammation that might benefit the pharmaceutical pipeline, and provide biomarkers for the stratification of patients with rheumatoid arthritis, for predicting remission, and - potentially - for use as rapid outcome measures. It is anticipated that panels of biomarkers will be derived from an immunological toolkit (Workpackage 2), developed from deep immune and clinical phenotyping of a large cohort of patients with new onset RA. The cohort components of this RA-MAP Consortium are central to Workpackage 1). A consortium agreement has been constructed to facilitate these interactions.
Collaborator Contribution Industry partners have been involved from the very outset (including the review and revision of the MRC programme application) in the design and implementation of the project. The project steering committee includes membership from each industry partner, while the project management board is chaired by an industry partner. For WP1, industry partners have reviewed the study protocol and related paperwork for the TACERA study - a longitudinal observational study of patients with RA - which will be used as the "substrate" for developing the immunological toolkit (WP2). Industry partners are also represented on the joint Study Steering and Data Monitoring Committee (SSDMC), and include an independent statistician who has reviewed the statistical analytical plan.
Impact 1. Contributions to study design 2. Review of study documents 3. Statistical review. 4. Input and support into study set up and logistics 5. Representation on the SSDMC 6. Representation on the Consortium Steering Committee and Management Board. Expertise as "In kind contributions" from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Start Year 2011
 
Description Rheumatology Regional Meeting, Newcastle, 2018 
Organisation University of Birmingham
Department Birmingham Clinical Trials Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Meeting hosts with multiple presentations.
Collaborator Contribution Successful regional meeting highlighting work taking place within the Rheumatoid Arthritis Centre of Excellence with talks from Iain McInnes, Chris Buckley, Andrew Filer, and Francesca Barone.
Impact Further collaborations and grant applications anticipated - especially imaging and cytometry.
Start Year 2018
 
Description Rheumatology Regional Meeting, Newcastle, 2018 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Meeting hosts with multiple presentations.
Collaborator Contribution Successful regional meeting highlighting work taking place within the Rheumatoid Arthritis Centre of Excellence with talks from Iain McInnes, Chris Buckley, Andrew Filer, and Francesca Barone.
Impact Further collaborations and grant applications anticipated - especially imaging and cytometry.
Start Year 2018
 
Description SOMAlogic (CRO) 
Organisation SomaLogic
Country United States 
Sector Private 
PI Contribution Plasma samples from RA-MAP TACERA study and Vaccine study were provided for SOMAscan proteomics analysis, The resulting data have been extensively analysed by the industry members of the RA-MAP consortium. The cost of the analysis has been covered by crowd sourcing amongst the RA-MAP industry partners (£90K).
Collaborator Contribution Provision of SOMAscan proteomics analysis of TACERA baseline and 6 month plasma samples, and healthy control samples from the vaccine study.
Impact RA disease stratification of TACERA patients.
Start Year 2016
 
Description SimOmics Ltd 
Organisation Simomics Ltd
Country United Kingdom 
Sector Private 
PI Contribution Provision of RA-MAP omics dataset for systems immunology collaborative project
Collaborator Contribution SimOmics has been working closely with the team of systems immunologists in the RA-MAP consortium since Q1 2016. They contribute with systems analysis of RA-MAP RA omics database and metabolic flux analysis.
Impact None yet
Start Year 2016
 
Description Tepnel Pharma Services 
Organisation Tepnel Pharma Services
Country United Kingdom 
Sector Private 
PI Contribution Providing biological materials arising from TACERA clinical study cohort for RNA processing
Collaborator Contribution RNA processing and miicroarray services for samples deried from TACERA clinical study
Impact Tepnel has taken up the role of RNA processing and RNA microarray which feeds directly into Transcriptomics package of RA-MAP.
Start Year 2015
 
Description WTCHG for NGS 
Organisation University of Oxford
Department Oxford Genomics Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution RA-MAP has provided RNA samples from TACERA clinical study cohort.
Collaborator Contribution Oxford Genomics has provided next generation sequencing of TACERA study RNA materials.
Impact Oxford Genomics has provided expertise in generating NGS data for RA-MAP consortium.
Start Year 2015
 
Title The APIPPRA study - Arthritis Prevention in the Pre-Clinical Phase of RA with Abatacept 
Description The APIPPRA study is one of the largest double blind placebo controlled clinical trials aimed at prevention of RA. The study completed recruitment in December 2018 and the data lock is projected for Q1 2021. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Clinical
Year Development Stage Completed 2019
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Results will read out in 2021 
URL http://www.isrctn.com/ISRCTN46017566
 
Description "Bones" Exhibition at the Great North Museum 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Workshops, demonstrations, talk, events and public information materials presented in parallel with the Bones Exhibition at the Great North Museum highlighting musculoskeletal research at our Centres of Excellence at Newcastle University including the Centre for Integrated Musculoskeletal Ageing, the Newcastle Experimental Arthritis Treatment Centre, the Rheumatoid Arthritis Centre of Excellence and the Newcastle Biomedical Research Centre.
Year(s) Of Engagement Activity 2017
URL https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world
 
Description 'Behind the scenes' - open evening event at the Manchester Royal Infirmary rheumatology department 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact "Behind the scenes" - open evening event was held at the Manchester Royal Infirmary rheumatology department, May 2015. Patients and carers were invited to meet staff and discuss research options - talks, examples of how research is conducted, opportunity to speak to research staff
Year(s) Of Engagement Activity 2015
 
Description 'Platform for Investigation' Event at Manchester Muserum of Science and Industry 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Manchester researchers were involved in awareness-raising activities at the Manchester Museum of Science and Industry held in April 2015. One day event with 800+ visitors, mainly families with children.
Year(s) Of Engagement Activity 2015
URL http://www.cmft.nhs.uk/media-centre/latest-news/explore-joints-and-genes-at-the-museum-of-science-an...
 
Description ADARRC - RA Summit - Abu Dhabi 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The 7th annual Abu Dhabi Advanced Rheumatology Review Course provided a comprehensive update on adult and paediatric rheumatology. Designed as a three-day, intensive rheumatology course, ADARRC is a series of lectures and workshops delivered by global experts to provide new insights, case studies and pioneering research findings.
Year(s) Of Engagement Activity 2017
URL http://adarrc.org/
 
Description Altnagelvin Hospital CTRIC Arthritis Open Eneving 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact This was a talk I was invited to do discussing prevention of RA and what risk factors we know about already
Year(s) Of Engagement Activity 2015
 
Description American College of Rheumatology (November 2015, California) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact PREVeNT RA Serum Biomarkers abstract was an abstract for a talk given by Prof Bruce at the ACR (American College of Rheumatology) November 2015
Year(s) Of Engagement Activity 2015
 
Description Antigen-Specific Immune Tolerance Europe, London, 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presented on RA-MAP and the TRC as examples of acadaemia-industry collaboration. Useful industry contacts on peptide therapeutics, CAR T-cells and other biotechnologies.
Year(s) Of Engagement Activity 2018
URL https://www.as-immunetolerance-eu.com/
 
Description Arthritis Research UK CSG Meeting 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Autumn F2F Meeting
Year(s) Of Engagement Activity 2016
 
Description BRC Celebration Event (December 2016, Manchester) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This event brought together university and hospital staff from across the city to disucss the BRC future plans and vision
Year(s) Of Engagement Activity 2016
 
Description BRC Scientific Advisory Board Meeting (January 2018) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The BRC SAB was to reflect on the initial year of the BRc and discuss strategy and receive international expert input on our short term objectives and our medium term strategy
Year(s) Of Engagement Activity 2018
 
Description Biomedical Research Unit Open Day (Manchester) - Disease Prevention 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Biomedical Research Unit (Musculoskeletal) in Manchester held its annual open day in May 2014, with this year's theme being on disease prevention. The open day provided staff from the regional institutions, hospitals and members of public to learn more about the research being carried out into disease prevention. This included a presentation given by Professor Ian Bruce on the PREVeNT RA study, introducing the study focussed on prevention of rheumatoid arthritis.

Increased public awareness of currently on-going studies aimed at disease prevention, in particular rheumatoid arthritis.
Year(s) Of Engagement Activity 2014
 
Description CRUK-ARUK Immune Homeostasis Innovation Workshop - Oxford 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Researchers and clinicians sharing information on homeostatic mechanisms in immunological systems.
Year(s) Of Engagement Activity 2017
URL http://www.arthritisresearchuk.org/research/news-for-researchers/2018/january/funding-partnership-wi...
 
Description Cafe Scientifique (PREVeNT RA), Cockermouth, Cumbria 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Professor Ian Bruce (PI for the PREVeNT RA study) gave a presentation of arthritis, based on his research. It provoked significant discussion about how lifestyle may influence arthritis development.
Year(s) Of Engagement Activity 2015
 
Description Cafe Scientifique (PREVeNT RA), Pendle, Lancashire 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Professor Ian Bruce (PI for the PREVeNT RA study) gave a presentation of arthritis, based on his research. It provoked significant discussion about how lifestyle may influence arthritis development.

Professor Bruce has been invited to give a further talk and the group sent a recording of his talk to other similar groups in England to raise awareness.
Year(s) Of Engagement Activity 2014
 
Description Cafe Scientifique, Cockermouth, Cumbria 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact I spoke to this group on arthritis research including prevention of RA and treatments for OA
Year(s) Of Engagement Activity 2015
 
Description Conservative Muslim Forum 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact This meeting in the House of Lords gave me the opportunity to talk about arthritis and its burden in the community as well as new approaches to treatment and prevention
Year(s) Of Engagement Activity 2015
 
Description Conservative Muslim Forum (London) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Professor Ian Bruce presented a talk to explore the question "Precision Medicine : An Achievable Goal?"
He discussed how precisely can diseases be treated in a way that is specific to the individual patient. He gave an in depth analysis of research in Rheumatology and the fact that there are 8 million people affected by the disease. Despite the complexity of the subject, Professor Bruce managed to make it accessible to the layman.
Professor Bruce alos talked about how research in the UK is fundedm and gave a breakdown of the various research being done by Medical Research Council and the National Institute of Health Research. Whilst the NHS's total budget is over £100 billion, the share devoted to research is under 3%.
For most people, the most fascinating part of the evening was listening to Professor Bruce on the general theme of medication. He he talked about medicine being "partly art, partly science." Most drugs prescribing is on a trial and error / best guess basis, using the likely benefit to the average person. He talked about "personalised medicine" which would target the medicine to the individual patient, and "stratified medicine" which groups patients into categories to assess which medicine to use, being intermediate between using data for the average person and data for the specific individual.
Year(s) Of Engagement Activity 2015
URL http://www.conservativemuslimforum.com/news~events/news-&-past-events/health-event-precision-medicin...
 
Description Consortium meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The RA-MAP TACERA study was included in a short presentation to the members of the EU Horizon 2020 Consortium RTCure
Year(s) Of Engagement Activity 2017
 
Description Drug Discovery Catapult - Alderley Park 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact Discussions with the Medicines Discovery Catapult around access by SMEs to RA-MAP biobanked samples.
Year(s) Of Engagement Activity 2017
URL https://md.catapult.org.uk/
 
Description EULAR AGM planning meeting, Zurich 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This is the committee that plans the annual scientific meeting for the European League Against Rheumatism.
Year(s) Of Engagement Activity 2017
URL http://www.eular.org
 
Description EULAR Conference (poster presentation, June 2015, Rome) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Data from our PREVENT RA programme presented
Year(s) Of Engagement Activity 2015
 
Description EULAR Therapeutic Drug Monitoring Study Group, Amsterdam, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chaired this EULAR Study Group reviewing therapeutic drug monitoring. Decision taken to apply for EULAR Task Force status in 2019.
Year(s) Of Engagement Activity 2018
URL https://www.eular.org/clinical_affairs_study_groups.cfm
 
Description Genesis Conference (London) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Dr Mike Barnes presented a talk entitled: Technologies empowering Omics in the sessioin "Empowering Technologies"
Year(s) Of Engagement Activity 2015
URL http://www.cambridgeahead.co.uk/2015/12/genesis-2015-london-10th-december/
 
Description How Precision Medicine will Transform Healthcare ( March 2018, Manchester) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact This meeting was part of our BRC seminar series and discussed precision medicine and presented exemplars of current studies
Year(s) Of Engagement Activity 2017,2018
 
Description Immune mediated Inflammatory Diseases Workshop: Wellcome Trust 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This 2 day workshop brought together a wide spectrum of experts across immune mediated diseases to discuss challenges and future opportunities to learn more about immune mediated conditions. Several potential collaborations were discussed
Year(s) Of Engagement Activity 2017
 
Description International Psoriasis Council Symposium, Munich September 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I spoke on P4 medicine in rheumatology and how such an approach can better address patient stratification
Year(s) Of Engagement Activity 2016
 
Description Inventory of Trials Study Workshop on Predictors of Remission Study 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Workshop for the Predictors of Remission study was organised in Manchester by Prof Jane Worthington, Prof Deborah Symmons, Prof Ian Bruce and Ms Fiona Stirling. The workshop provided an opportunity to feed back information and analyses of the pooled clinical datasets from the 7 consortium member organisations. The meeting was successful, supported by approximately 20 participants contributing from these organisations (mixture of academic and industry partners).

The findings of the study are planned to be incorporated into a manuscript under preparation by Prof Deborah Symmons. This workshop also promoted further data to be produced in order to strengthen the powering of the results. In addition, Brian Tom (study statistician for the RA-MAP consortium) was invited to speak at PSI (Statisticians in the Pharmaceutical Industry) conference in May 2015.
Year(s) Of Engagement Activity 2014
 
Description Kellgren @ 10 Manchester (December 2017, Manchester) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact This event was to update our patients and study participants on our research and progress with recent studies
Year(s) Of Engagement Activity 2017
 
Description Launch of the Medicines Discovery Catapult (January 2017, Alderley Park) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact The Catapult is an important partner for our BRC and this launch event introduced us to new collaborators and potential funding streams
Year(s) Of Engagement Activity 2018
 
Description Lecture on "Stratified approaches to the treatment of rheumatoid arthritis" (Newcastle University MSc in Genomic Medicine) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact Newcastle PI John Isaacs gave a lecture on stratified medicine in RA to the Genomics Medicine MSc at Newcastle University. This was provided to medical students who all work full time in the NHS.
Year(s) Of Engagement Activity 2016
 
Description MRC Immunopsychiatry Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact An MRC hosted workshop in immune aspects of psychiatry and psychiatric disorders in chronic autoimmune diseases
Year(s) Of Engagement Activity 2016
 
Description MRC Platforms Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Dr Michael Barnes presented a talk entitled "Platforms for Data integration"
Year(s) Of Engagement Activity 2015
 
Description MRC RA-MAP CMB and PSG Meetings London 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Strategic planning around future research directed at predictors of remission in RA.
Year(s) Of Engagement Activity 2016
 
Description MRC Research Strategy Visit 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Reviewed medical research at Newcastle highlighting achievements in experimental medicine and translational research and identifying improvement opportunities.
Year(s) Of Engagement Activity 2016
 
Description MRC Stratified Medicine Consortia in Immune-Inflammatory Diseases Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This workshop explored common characteristics across a number of key consortia and has helped to better understand common challenges in the mechanisms of these conditions as well as common methodological challenges
Year(s) Of Engagement Activity 2016
 
Description MRC Stratified Medicine Initiative - Strategy Workshop 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact MRC Stratified Medicine Strategy Workshop held on 4th July 2013 in London, UK.


Assisted the broader community in better understanding the opportunities and challenges posed by taking a stratified medicine approach
Year(s) Of Engagement Activity 2013
 
Description MRC Technology Strategy Board Stratified Medicine Showcase 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact An MRC Stratified Medicine showcase, held on October 31st 2013.

This provided an opportunity to highlight the activities of the RA-MAP consortium to potential applicants for MRC funded stratified medicine consortia.
Year(s) Of Engagement Activity 2013
 
Description MRC/ABPI RA-MAP Final Meeting - London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Sharing the research results of the RA-MAP project.
Year(s) Of Engagement Activity 2017
 
Description NHSA Meeting ( September 2017, Newcastle) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact NHSA meeting to plan collaborative work across the Northern BRCs
Year(s) Of Engagement Activity 2017
 
Description NIHR Manchester BRC PPI and E Training 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact I organised a BRC workshop for training on PPI and E. I opened the meeting with a talk around how the BRC prioritises PPIE and also participated in a workshop on study design and how patients can help improve study conduct and pragmatic aspects of studies.
Year(s) Of Engagement Activity 2017
 
Description NIHR Manchester BRC and CRF Newsletter (June 2017) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Supporters
Results and Impact Our BRC newsletter is read widely by our circulation list and helps publicise our work amongst key stakeholders
Year(s) Of Engagement Activity 2017
 
Description NIHR Northern Biomedical Research Centre`s Showcase (March 2018, Manchester) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact We presented the work of the Northern BRCs to industry in an event supported by the NHSA
Year(s) Of Engagement Activity 2018
 
Description NOVARTIS Biomedical Research Foundation (June 2017, Mayfair) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A meeting between NIHR and Novartis to discuss potential engagement of Novartis in the UK
Year(s) Of Engagement Activity 2017
 
Description Open Innovation in the NHS workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact On the 2nd April 2014 the Academy of Medical Sciences hosted a workshop in partnership with the Centre for the Advancement of Sustainable Medical Innovation (CASMI) to bring together members of academia, industry, the NHS, funding bodies and IP experts. The discussion focused on the key issues and opportunities surrounding collaboration with the NHS, focusing particularly on 'open innovation' models of partnership. Professor Andrew Cope (PI of RA-MAP study) contributed by presenting the MRC/ABPI-funded RA-MAP consortium as an exemplar of open innovation in the NHS and model of academia-NHS-industry collaboration.

Delegates enjoyed four case presentations that highlighted the advantages of open collaboration models and also some of the barriers and frustration involved with these partnerships. Following a candid and constructive period of discussion, delegates highlighted four areas that they considered to be the most significant barriers to open innovation. These were: lack of metrics, poor incentivisation and reward for innovation, cultural conflicts between sectors and poor use of existing structures. Delegates then worked in groups to consider novel solutions to overcoming these barriers and facilitate open innovation partnerships with the NHS.
Year(s) Of Engagement Activity 2014
URL http://www.acmedsci.ac.uk/policy/policy-projects/open-innovation-in-the-nhs/
 
Description Precision Medicine UK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact NOCRI joined UK leaders in the research, development and commercialisation of precision medicine for a one-day event this week designed to encourage new partnerships and highlight new opportunities in the field.

The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, on 9 December was organised on behalf of the Stratified Medicine Innovation Platform by Innovate UK,, National Institute for Health Research, Cancer Research UK,Medical Research Council, Invest Northern Ireland, Health and Care Research Wales and the Knowledge Transfer Network, with the NIHR Office for Clinical Research Infrastructure (NOCRI) coordinating the NIHR's involvement.

The day formed part of a programme to make the UK a world leader in precision medicine and provided real-world examples of the discovery and development of precision medicine solutions, through talks, panel discussions, workshops and exhibitions with the opportunity to arrange one-to-one partnering meetings.

Precision medicine is an emerging approach to the treatment and diagnosis of disease that takes into account variations in a patient's genes, environment and lifestyle. It aims to better target treatments to an individual's circumstances to improve outcomes for patients.

Representatives from across the NIHR were involved in the day and presented on a range of projects and funding programmes. Professor Bryan Williams of NIHR UCLH Biomedical Research Centre joined the first panel of the day which highlighted UK investments in the invention and evaluation phase of research. Professor Williams' highlighted key NIHR's investments in this space and provided examples of exciting precision medicine projects from UCLH BRC. In addition, a number of NIHR precision medicine projects were presented during the disease area specific showcase sessions. This included Professor Costantino Pitzalis who presented the THERAPIST study on behalf of the NIHR Translational Research Partnership, Professor Simon Mead's who presented a project at NIHR Queen's Square Biomedical Research Unit on the "dementia chip" and Professor Tariq Sadiq's who presented on Capacity Building and Delivery of Precision Medicine in Sexual Health, through NIHR Funding. Mark Samuels, Managing Director of NOCRI, also chaired a discussion panel themed 'Enabling Collaboration', which highlighted the value of collaborative working between companies, academics, charities and patients.

The event saw the launch by the chief executive of Innovate UK, Dr Ruth McKernan, of a new map of the precision medicine landscape.

A whole range of organisations, including charities, health bodies and devolved administrations are coordinating their work under the umbrella of Innovate UK's Stratified Medicine Innovation Platform, with NOCRI representing the NIHR.
Year(s) Of Engagement Activity 2015
URL http://www.uk-pgx-stratmed.co.uk/index.php/event-calendar/icalrepeat.detail/2015/12/09/213/73/-
 
Description RA-MAP Biostatistics overview (presentation at MATURA meeting) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact RA-MAP Biostatistics Overview was presented by Brian Tom (RA-MAP statistician PI) at MATURA Scientific Meeting, where the statistical approaches used in RA-MAP were outlined, which may be relevant to the MRC Stratified Medicine Initiative MATURA consortium
Year(s) Of Engagement Activity 2017
 
Description RA-MAP Presentation at PSI Immunology Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Brian Tom, the leading PI statistician of RA-MAP, provided RA-MAP project overview and statistical approaches taken in a presentation given at PSI (Promoting Statistical Insight) Immunology meeting to industry statisticians.
Year(s) Of Engagement Activity 2016
 
Description RA-MAP data infrastructure and analysis strategy presented at Wellcome Trust Immune Modulated Inflammatory Disease Workshop (Feb 2017) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact RA-Map data infrastructure and analysis strategy was presented
Year(s) Of Engagement Activity 2017
 
Description RA-MAP data infrastructure was presented as an exemlar at the MRC Stratified Medicine Applicats Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact RA-Map data infrastructure was presented as an exemplar at the MRC Stratified Medicine applicants workshop
Year(s) Of Engagement Activity 2017
 
Description RA-MAP project presentation as a Startified Medicine exemplar at the MRC-eMedLab Stratified Medicine Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA-Map project was presented as a Stratified Medicine exemplar at the MRC-eMedLab Stratified Medicine workshop
Year(s) Of Engagement Activity 2016
 
Description RA/MAP Closure meeting (June 2017, London) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Closure of the RA MAP consortium with presentations on relevant outputs and future plans
Year(s) Of Engagement Activity 2017
 
Description RACE Scientific Meeting - Glasgow 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. This was the annual scientific meeting.
Year(s) Of Engagement Activity 2017
URL http://www.race-gbn.org/
 
Description RTCure Kick Off Meeting - Stockholm 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Rheumatoid arthritis (RA) occurs when the immune system attacks the joints. Symptoms include painful, swollen joints, stiffness, and fatigue, all of which affect patients' quality of life. Although RA treatments exist, many patients still struggle to keep their condition under control and many experience unpleasant and sometimes serious side effects of their treatment. Furthermore, there are currently no approved drugs for the early phases of RA.

The RTCure project aims to develop knowledge and tools to aid in the development of treatments for people in the earliest stages of the disease as well as those at risk of developing it. As such, the team will develop and validate new methods to identify people at high risk for RA and tools to monitor the progress of the disease. They will also validate methods to monitor immune tolerance treatments; highly-targeted medicines that stop the immune system's attacks on the joints while ensuring the immune system remains able to fight off infections.

In the long term, the project hopes that its findings will deliver treatments capable of preventing the disease in those at risk of RA, and curing it in people who are still in the early stages of the disease.
Year(s) Of Engagement Activity 2017
URL https://www.imi.europa.eu/projects-results/project-factsheets/rtcure
 
Description Rheumatology Research Patient Partnership (R2P2) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Education and empowering Patient Partners to participate in research design and oversight. The Rheumatology Research Group in Birmingham recognise the importance of involvement of patients and members of the general public in all aspects of the research process, including initial project development and grant applications, the design and implementation of the studies as well as their dissemination.

Patients was given an opportunity to have their say in research that is potentially for their benefit.
Year(s) Of Engagement Activity 2014
URL http://www.birmingham.ac.uk/research/activity/mds/projects/ii/R2P2/index.aspx
 
Description Rise Up, London, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact New working group of rheumatologists, gastroenterologists and dermatologists developing educational materials across the immune-mediated inflammatory diseases.
Year(s) Of Engagement Activity 2018
 
Description Seminar at Altnagelvin Hospital 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Prof Ian Bruce provided a seminar about pevention of RA based on PREVENT RA study.
Year(s) Of Engagement Activity 2015
 
Description Site Visit Arthritis UK (October 2017) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact PREVeNT RA poster was for a poster presentation at the site visit from the funding body Arthritis Research UK which took place in October 2017 our MASTERPLANS studies were also highlighted as part of our precision medicine workplans
Year(s) Of Engagement Activity 2017
 
Description TACERA Premier 2 London 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Hosted the day. Introductory Presentation.
Year(s) Of Engagement Activity 2016
 
Description TACERA study Investigator Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact This Investigator meeting was hosted by GSK in September 2013. It brought together participating recruitment centres rom across the UK, including members of the RA-MAP consortium to discuss the study and encourage recruitment of study subjects. This provided an excellent opportunity for the RA-MAP investigators to talk about this MRC initiative to a wider research community.

It is anticipated that this meeting will facilitate patient recruitment to the TACERA study.
Year(s) Of Engagement Activity 2013
 
Description Translational Research Collaboration Steering Group Meeting (February 2018) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The quarterly TRC meetings help us to develop a strategy for the TRC and industry links including new SLE and RA studies/trials
Year(s) Of Engagement Activity 2018
 
Description Visit to China to key universities (January 2018, China) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Our university visited 4 Chinese universities. We planned and discussed future collaborations including student exchanges, collaborative grants and future visits
Year(s) Of Engagement Activity 2018